Ondine Biomedical Secures First NHS Commercial Deal with Steriwave Technology
TL;DR
Ondine Biomedical Inc sealed its first commercial deal with an NHS trust, gaining an early advantage in the healthcare market.
The success is attributed to Steriwave's effectiveness in reducing the need for antibiotics, leading to broader NHS adoption and deployment in healthcare facilities.
Ondine Biomedical's Steriwave is making the world a better place by improving healthcare outcomes, reducing antibiotic use, and contributing to antimicrobial resistance efforts.
Ondine Biomedical Inc is expanding its international presence in Canada, UK, and Spain, while also exploring potential in the United States through FDA phase three trials.
Found this article helpful?
Share it with your network and spread the knowledge!
Ondine Biomedical Inc. has achieved a significant milestone by securing its first commercial agreement with an NHS trust in the United Kingdom for its Steriwave antimicrobial photodisinfection technology. The adoption by Pontefract and Pinderfields hospitals follows a successful 500-patient elective hip and knee surgical quality initiative conducted at Pontefract, demonstrating the technology's effectiveness in clinical settings. This commercial deployment marks a crucial step in expanding non-antibiotic approaches to infection prevention within the UK healthcare system.
Matt Ross, Vice President of Sales & Marketing at Ondine Biomedical, expressed enthusiasm about this development, noting that it comes after demonstrating positive patient outcomes and favorable health economics. The company now aims to develop a comprehensive business case in collaboration with the York health economics group and Mid Yorkshire to support broader NHS adoption across the United Kingdom. This strategic approach leverages the successful results from the initial implementation to build a compelling case for wider healthcare system integration.
The UK adoption represents part of Ondine's growing commercial momentum globally. The Steriwave technology is now deployed in eight new healthcare facilities, bringing the total to 22 facilities across Canada while expanding its presence in both the UK and Spanish markets. This expansion is supported by the technology's demonstrated effectiveness in reducing antibiotic usage, as shown in a UK study, and its strong alignment with global antimicrobial resistance mitigation efforts. The technology's ability to provide an alternative to traditional antibiotics addresses a critical need in modern healthcare systems worldwide.
Looking forward, Ondine Biomedical plans to continue its European market expansion while capitalizing on existing success in Canada. The company is also exploring potential entry into the United States market through FDA phase three clinical trials. Ondine's innovative antimicrobial photodisinfection approach positions the company as a promising contributor to the global fight against antibiotic resistance and healthcare-associated infections, offering a technology that could significantly impact infection control practices across multiple healthcare settings and geographic regions.
Curated from News Direct
